Literature DB >> 24616135

Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

Matthew Herder, Elaine Gibson, Janice Graham, Joel Lexchin, Barbara Mintzes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24616135      PMCID: PMC4016092          DOI: 10.1503/cmaj.131850

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  23 in total

1.  Medicine. Moving toward transparency of clinical trials.

Authors:  Deborah A Zarin; Tony Tse
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

Review 2.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

3.  Access to patient-level trial data--a boon to drug developers.

Authors:  Hans-Georg Eichler; Frank Pétavy; Francesco Pignatti; Guido Rasi
Journal:  N Engl J Med       Date:  2013-10-21       Impact factor: 91.245

Review 4.  Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies.

Authors:  Joel Lexchin; Orla O'Donovan
Journal:  Soc Sci Med       Date:  2009-09-24       Impact factor: 4.634

5.  Provincial drug plan officials' views of the Canadian drug safety system.

Authors:  Joel Lexchin; Mary Wiktorowicz; Kathy Moscou; Laura Eggertson
Journal:  J Health Polit Policy Law       Date:  2013-02-15       Impact factor: 2.265

6.  The administration and development of federal statutes on foods and drugs in Canada.

Authors:  L I Pugsley
Journal:  Med Serv J Can       Date:  1967-03

7.  CANADIAN THALIDOMIDE EXPERIENCE.

Authors:  J F WEBB
Journal:  Can Med Assoc J       Date:  1963-11-09       Impact factor: 8.262

8.  Notice of compliance with conditions: a policy in limbo.

Authors:  Joel Lexchin
Journal:  Healthc Policy       Date:  2007-05

9.  The imperative to share clinical study reports: recommendations from the Tamiflu experience.

Authors:  Peter Doshi; Tom Jefferson; Chris Del Mar
Journal:  PLoS Med       Date:  2012-04-10       Impact factor: 11.069

10.  The quality of registration of clinical trials.

Authors:  Roderik F Viergever; Davina Ghersi
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

View more
  2 in total

1.  Can reporting of adverse drug reactions create safer systems while improving health data?

Authors:  Corinne Hohl; Joel R Lexchin; Ellen Balka
Journal:  CMAJ       Date:  2015-05-04       Impact factor: 8.262

2.  A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.

Authors:  Steven G Morgan; Marc-André Gagnon; Barbara Mintzes; Joel Lexchin
Journal:  Healthc Policy       Date:  2016-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.